Abstract
Clinical and research practices designed by developed countries are often implemented in host nations of the Third World. In recent years, a number of papers have presented a diversity of arguments to justify these practices which include the defence of research with placebos even though best proven treatments exist; the distribution of drugs unapproved in their country of origin; withholding of existing therapy in order to observe the natural course of infection and disease; redefinition of equipoise to a more bland version, and denial of post-trial benefits to research subjects.
These practices have all been prohibited in developed, sponsoring countries, even though they invariably have pockets of poverty where conditions comparable to the Third World prevail. Furthermore, the latest update of the Declaration of Helsinki clearly decries double ethical standards in research protocols. Under these circumstances, it does not seem appropriate that First World scholars should propose and defend research and clinical practices with less stringent ethical standards than those mandatory in their own countries.
Recent years have witnessed frequent reports of less stringent ethical standards being applied to both clinical and research medical practices, for the most part in the field of drug trials and drug marketing, initiated by developed countries in poorer nations. Still more unsettling, a number of articles have endorsed the policy of employing ethical norms in these host countries, which would be unacceptable to both the legislations and the moral standards of the sponsor nations. Also, these reformulations often contravene the Declaration of Helsinki or one of its updates. This paper is not so much concerned with the actual practices, which have been subjected to frequent scrutiny and publicly decried when gross misconduct occurred. Rather, my concern relates to the approval and support such practices have found in the literature on bioethics from authors who might be expected to use their energy and scholarship to explore and endorse the universalisability of ethics rather than to develop ad hoc arguments that would allow exceptions and variations from accepted moral standards. To this purpose, issue will be taken with arguments in three fields: medical and pharmaceutical practices, research strategies, and local application of research results.
Full Text
The Full Text of this article is available as a PDF (85.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Angell M. The ethics of clinical research in the Third World. N Engl J Med. 1997 Sep 18;337(12):847–849. doi: 10.1056/NEJM199709183371209. [DOI] [PubMed] [Google Scholar]
- Bloom B. R. The highest attainable standard: ethical issues in AIDS vaccines. Science. 1998 Jan 9;279(5348):186–188. doi: 10.1126/science.279.5348.186. [DOI] [PubMed] [Google Scholar]
- Caplan A. L. Twenty years after. The legacy of the Tuskegee Syphilis Study. When evil intrudes. Hastings Cent Rep. 1992 Nov-Dec;22(6):29–32. [PubMed] [Google Scholar]
- Clark P. A. The ethics of placebo-controlled trials for perinatal transmission of HIV in developing countries. J Clin Ethics. 1998 Summer;9(2):156–166. [PubMed] [Google Scholar]
- Cooley D. R. Distributive justice and clinical trials in the Third World. Theor Med Bioeth. 2001 Jun;22(3):151–167. doi: 10.1023/a:1011452716028. [DOI] [PubMed] [Google Scholar]
- Cooley D. Good enough for the Third world. J Med Philos. 2000 Aug;25(4):427–450. doi: 10.1076/0360-5310(200008)25:4;1-A;FT427. [DOI] [PubMed] [Google Scholar]
- Crouch R. A., Arras J. D. AZT trials and tribulations. Hastings Cent Rep. 1998 Nov-Dec;28(6):26–34. [PubMed] [Google Scholar]
- Glantz L. H., Annas G. J., Grodin M. A., Mariner W. K. Research in developing countries: taking "benefit" seriously. Hastings Cent Rep. 1998 Nov-Dec;28(6):38–42. [PubMed] [Google Scholar]
- Grady C. Science in the service of healing. Hastings Cent Rep. 1998 Nov-Dec;28(6):34–38. [PubMed] [Google Scholar]
- Jones J. H. The Tuskegee legacy. AIDS and the black community. Hastings Cent Rep. 1992 Nov-Dec;22(6):38–40. [PubMed] [Google Scholar]
- Levine C. Placebos and HIV. Lessons learned. Hastings Cent Rep. 1998 Nov-Dec;28(6):43–48. [PubMed] [Google Scholar]
- Levine R. J. The "best proven therapeutic method" standard in clinical trials in technologically developing countries. J Clin Ethics. 1998 Summer;9(2):167–172. [PubMed] [Google Scholar]
- London A. J. The ambiguity and the exigency: clarifying 'standard of care' arguments in international research. J Med Philos. 2000 Aug;25(4):379–397. doi: 10.1076/0360-5310(200008)25:4;1-A;FT379. [DOI] [PubMed] [Google Scholar]
- Lurie P., Wolfe S. M. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med. 1997 Sep 18;337(12):853–856. doi: 10.1056/NEJM199709183371212. [DOI] [PubMed] [Google Scholar]
- Robb M. L., Khambaroong C., Nelson K. E. Studies in Thailand of the vertical transmission of HIV. N Engl J Med. 1998 Mar 19;338(12):843–844. doi: 10.1056/NEJM199803193381215. [DOI] [PubMed] [Google Scholar]
- Rothman D. J. Were Tuskegee & Willowbrook 'studies in nature'? Hastings Cent Rep. 1982 Apr;12(2):5–7. [PubMed] [Google Scholar]